

February 27, 2009

Whom It May Concern

KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,
Chiyoda-ku, Tokyo
Securities code; 4569, TSE 1st Section

Execution of Licensing and Supply Agreement on Uritos[®] Tablets with SPIMACO

KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo, President: Itaru Kojo) has entered into a License and Supply Agreement with Saudi Pharmaceutical Industries & Medical Appliances Corporation ("SPIMACO") (Head office: Riyadh, Saudi Arabia, President: Dr. Abdullah Bin Abdulaziz Al Abdulkader), under which KYORIN Pharmaceutical granted to SPIMACO an exclusive right to develop, register, import, and market Uritos[®] Tablets (generic name: Imidafenacin), a therapeutic agent for overactive bladder (OAB) in thirteen countries in the Middle East and North Africa (MENA) region, including Saudi Arabia.

Uritos[®] Tablets is an anticholinergic agent exerting selective antagonist actions on M₃ and M₁ muscarinic subtype receptors and improves urgency, urinary frequency and urge urinary incontinence associated with OAB, which has a characteristic safety profile, such as low incidence of dry mouth due to its high selective actions on the bladder. In Japan, KYORIN Pharmaceutical and Ono Pharmaceutical Co., Ltd. are currently marketing this agent under the brand names of Uritos[®] Tablets and Staybla[®] Tablets respectively (launched in June 2007).

Taking this alliance opportunity with SPIMACO, a leading pharmaceutical company in Saudi Arabia, with Uritos[®] Tablets which is KYORIN's first product expected to be launched in the region, KYORIN Pharmaceutical wishes to spread its global business activities.

KYORIN Pharmaceutical is to be contributing to OAB patients by means of improvement of their quality of life through early penetration of Uritos[®] Tablets into the Japanese market.

###

Contacts:

Management Planning Department
K Y O R I N C o . , L t d .
T E L : 3 - 3 2 9 3 - 3 4 1 4
F A X : 3 - 3 2 9 3 - 3 4 5 4

About SPIMACO

Foundation: January 1986
President: Dr. Abdullah Bin Abdulaziz Al Abdulkader
Revenue: SAR 872 million (2008)
Employees: 972 (as of December 31, 2008)
Features: SPIMACO is the No.1 local pharmaceutical company and listed in Saudi stock market. It has developed a strong position in the urology field. SPIMACO has established various business partnerships with multinational pharmaceutical/biotech companies. For more information, visit <http://www.spimaco.com.sa/eindex.htm>.

About KYORIN Pharmaceutical

Foundation: December 1923
President and CEO: Itaru Kojo
Revenue: JPY 70.5 billion (March 31, 2008)
Employees: 1,517 (as of March 31, 2008)

Features: KYORIN Pharmaceutical is aiming at its corporate vision of becoming an integrated, trusted and unique healthcare organization based on global drug discovery operations. It is pursuing evolution of its drug discovery business model and establishment of new operations which may support its drug discovery business. KYORIN Pharmaceutical is focusing its marketing efforts and resources on the fields of respiratory, otolaryngology and urology, and its R&D efforts and resources on the areas of infectious, immunological/allergic and metabolic diseases. For more information, visit <http://www.kyorin-pharm.co.jp/en/>.